Frasor Jonna, Danes Jeanne M, Komm Barry, Chang Ken C N, Lyttle C Richard, Katzenellenbogen Benita S
Department of Molecular and Integrative Physiology, University of Illinois, Urbana, Illinois 61801, USA.
Endocrinology. 2003 Oct;144(10):4562-74. doi: 10.1210/en.2003-0567. Epub 2003 Jul 10.
Estrogens are known to regulate the proliferation of breast cancer cells and to alter their cytoarchitectural and phenotypic properties, but the gene networks and pathways by which estrogenic hormones regulate these events are only partially understood. We used global gene expression profiling by Affymetrix GeneChip microarray analysis, with quantitative PCR verification in many cases, to identify patterns and time courses of genes that are either stimulated or inhibited by estradiol (E2) in estrogen receptor (ER)-positive MCF-7 human breast cancer cells. Of the >12,000 genes queried, over 400 showed a robust pattern of regulation, and, notably, the majority (70%) were down-regulated. We observed a general up-regulation of positive proliferation regulators, including survivin, multiple growth factors, genes involved in cell cycle progression, and regulatory factor-receptor loops, and the down-regulation of transcriptional repressors, such as Mad4 and JunB, and of antiproliferative and proapoptotic genes, including B cell translocation gene-1 and -2, cyclin G2, BCL-2 antagonist/killer 1, BCL 2-interacting killer, caspase 9, and TGFbeta family growth inhibitory factors. These together likely contribute to the stimulation of proliferation and the suppression of apoptosis by E2 in these cells. Of interest, E2 appeared to modulate its own activity through the enhanced expression of genes involved in prostaglandin E production and signaling, which could lead to an increase in aromatase expression and E2 production, as well as the decreased expression of several nuclear receptor coactivators that could impact ER activity. Our studies highlight the diverse gene networks and metabolic and cell regulatory pathways through which this hormone operates to achieve its widespread effects on breast cancer cells.
已知雌激素可调节乳腺癌细胞的增殖,并改变其细胞结构和表型特性,但雌激素调节这些事件的基因网络和途径仅得到部分了解。我们使用Affymetrix基因芯片微阵列分析进行全基因组表达谱分析,并在许多情况下通过定量PCR进行验证,以确定雌激素受体(ER)阳性的MCF-7人乳腺癌细胞中受雌二醇(E2)刺激或抑制的基因模式和时间进程。在查询的12000多个基因中,超过400个呈现出强烈的调控模式,值得注意的是,大多数(70%)基因表达下调。我们观察到阳性增殖调节因子普遍上调,包括生存素、多种生长因子、参与细胞周期进程的基因以及调节因子-受体环,而转录抑制因子如Mad4和JunB以及抗增殖和促凋亡基因如B细胞易位基因-1和-2、细胞周期蛋白G2、BCL-2拮抗剂/杀手1、BCL 2相互作用杀手、半胱天冬酶9和TGFβ家族生长抑制因子表达下调。这些共同作用可能促成了E2对这些细胞增殖的刺激和凋亡的抑制。有趣的是,E2似乎通过增强参与前列腺素E产生和信号传导的基因表达来调节自身活性,这可能导致芳香化酶表达增加和E2产生增加,以及几种可能影响ER活性的核受体共激活因子表达降低。我们的研究突出了该激素发挥作用以对乳腺癌细胞产生广泛影响所涉及的多样基因网络以及代谢和细胞调节途径。